
    
      A pilot open-label single arm multicenter phase 0 window of opportunity study of BTG-002814
      given up to 3 weeks prior to surgery in up to 12 patients with resectable Hepatocellular
      carcinoma (HCC) or Colorectal cancer (CRC) with liver metastases.
    
  